| Literature DB >> 25019209 |
Cameron B Williams1, Meghan C Hughes2, Brittany A Edgett1, Trisha D Scribbans1, Craig A Simpson3, Christopher G R Perry2, Brendon J Gurd1.
Abstract
The current study tested the hypothesis that a single, moderate dose of RSV would activate the AMPK/SIRT1 axis in human skeletal muscle and adipose tissue. Additionally, the effects of RSV on mitochondrial respiration in PmFBs were examined. Eight sedentary men (23.8±2.4 yrs; BMI: 32.7±7.1) reported to the lab on two occasions where they were provided a meal supplemented with 300 mg of RSV or a placebo. Blood samples, and a muscle biopsy were obtained in the fasted state and again, with the addition of an adipose tissue biopsy, two hours post-prandial. The effect of RSV on mitochondrial respiration was examined in PmFBs taken from muscle biopsies from an additional eight men (23.4±5.4 yrs; BMI: 24.4±2.8). No effect of RSV was observed on nuclear SIRT1 activity, acetylation of p53, or phosphorylation of AMPK, ACC or PKA in either skeletal muscle or adipose tissue. A decrease in post absorptive insulin levels was accompanied by elevated skeletal muscle phosphorylation of p38 MAPK, but no change in either skeletal muscle or adipose tissue insulin signalling. Mitochondrial respiration in PmFBs was rapidly inhibited by RSV at 100-300 uM depending on the substrate examined. These results question the efficacy of a single dose of RSV at altering skeletal muscle and adipose tissue AMPK/SIRT1 activity in humans and suggest that RSV mechanisms of action in humans may be associated with altered cellular energetics resulting from impaired mitochondrial ATP production.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25019209 PMCID: PMC4096915 DOI: 10.1371/journal.pone.0102406
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Subject characteristic summary.
| Experiment 1 (n = 8) | Experiment 2 (n = 8) | |
| Age (yrs) | 23.8±2.4 | 23.4±5.4 |
| Height (cm) | 182.5±10.2 | 183.6±6.1 |
| Weight (kg) | 111.3±37.5 | 83.2±12.7 |
| BMI | 32.7±7.1 | 24.4±2.8 |
| Waist Circumference (cm) | 106.4±21.2 | 84.1±6.3 |
| VO2 peak (ml min−1 kg−1) | 34.0±7.3 | 50.0±8.7 |
Values are mean ± SD. yrs, years; cm, centimeters; kg, kilograms; BMI, body mass index.
*Significantly different (p<0.05) than participants from experiment 1.
Figure 1Both the activation of proteins implicated in SIRT1 activation and nuclear SIRT1 activity are unaltered following an acute dose of resveratrol in human skeletal muscle.
Skeletal muscle nuclear SIRT1 activity (A) in the fasted (light bars) and post-prandial state (dark bars) in both conditions; and cytosolic contamination (LDH protein content) of nuclear extracts is also shown. The change in phosphorylated and acetylated protein content (B) in the post-prandial (post) state (expressed relative to fasting) in the placebo (PL; open bars) and resveratrol (RSV; shaded bars) conditions. Representative blots for all proteins are shown (C). ‡ Significant effect (P<0.05) of time on phosphorylated protein content.
Figure 2Adipose tissue signaling is unaltered by resveratrol.
Phosphorylated protein content (A) in the post-prandial (post) state following resveratrol (RSV) expressed relative to placebo (PL). Representative blots for all proteins are also shown (B).
Changes in metabolic and plasma measures from fasting to the post-prandial state in both the Placebo and RSV conditions.
| Placebo | RSV | |||
| Fasted | Post-prandial | Fasted | Post-prandial | |
| VO2 (ml/min) | 307±108 | 340±97 | 373±111 | 387±124 |
| RER | 0.82±0.05 | 0.81±0.05 | 0.81±0.06 | 0.82±0.07 |
| Fatty Acid Oxidation (kcal/min) | 0.87±0.15 | 1.04±0.22 | 0.97±0.19 | 1.11±0.18 |
| Plasma Glycerol (mmol/L) | 0.08±0.02 | 0.07±0.03 | 0.10±0.03 | 0.08±0.04 |
| Plasma Insulin (µIU/L) | 7.2±3.5 | 27.6±5.7 | 7.8±3.3 | 19.0±2.5 |
| Plasma Glucose (mmol/L) | 5.1±0.2 | 5.2±0.2 | 5.3±0.3 | 5.0±0.3 |
Values are means ± SD. VO2, Oxygen uptake; RER, Respiratory Exchange Ratio; ml, millimeters; kcal, kilocalories; mmol, millimole; mIU, micro international units.
Significant effect (P<0.05) of time.
Significant interaction (P<0.05).
Figure 3Impact of an acute dose of resveratrol on 2
Plasma insulin (A) and plasma glucose (B) concentrations in the fasted (light bars) and post-prandial (dark bars) state. The change in phosphorylated protein content (C) in the post-prandial (post) state (expressed relative to fasting) in the placebo (PL; open bars) and resveratrol (RSV; shaded bars) conditions. Representative blots for all proteins are shown (D). * Significantly different (P<0.05) from fasted within same condition. † Significant interaction (P<0.05) between RSV and placebo.
Figure 4Resveratrol inhibits mitochondrial respiration in permeabilized muscle fibre bundles.
The effect of resveratrol or vehicle (DMSO) on substrate-specific respiration was determined by titrating resveratrol following the induction of state 3 respiration with either 10 mM glutamate (A), 10 mM succinate (B), 10 mM pyruvate (C) or 40 µM palmitoyl carnitine (D) with 5 mM malate in all protocols. Changes in mitochondrial respiration are expressed relative to maximal state 3 respiration determined immediately prior to the resveratrol titration. * Significantly different (P<0.05) from vehicle treatment.